ORLANDO, Fla., Jan. 7, 2016 (SEND2PRESS NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTC:MDIT, the "Company"), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces today that CEO, Michaela Ott and CFO, Robert McCullough will present at the SeeThruEquity First Annual Microcap Healthcare Investor Conference on Monday, January 11, 2016, at the Fairmont San Francisco in San Francisco, Calif.
MEDITE, a USA based company now public through the merger with CytoCore Inc. has emerged as a German manufacturer focused on global sales of cancer diagnostic tools consisting of anatomic pathology, histology and cytology laboratory equipment and supplies. Recent agreements with U.S. distribution partners, Hospital Group Purchasing Organizations along with our Chinese partner UNIC Medical will allow the company to focus growth from historically based European sales to entry into the U.S., Latin America and a burgeoning and untapped Chinese market.
UNIC Medical selling MEDITE's equipment, which is already Chinese FDA registered, and cytology assays and stains is involved with the Chinese government in establishing first time country pathology standards for digitalized computer aided diagnosis of cancer in China, a country of 1.4 billion people with a lack of sufficient number of pathologists. As the company expands consumable cytology sales for cervical and breast cancer worldwide, current profitability should significantly expand as margins increase in the near future.
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. SeeThruEquity has initiated coverage on numerous NYSE, NASDAQ, TSX, and OTC companies in a variety of industries including technology, health care, consumer, energy and special situations.
About MEDITE Cancer Diagnostics, Inc.:
MEDITE Cancer Diagnostics, Inc. is a Delaware registered company consisting of wholly-owned MEDITE GmbH a Germany-based company with its subsidiaries. On April 3, 2014, MEDITE was acquired by former CytoCore, Inc. a biomolecular diagnostics company engaged in the design, development, and commercialization of cost-effective cancer screening systems and Biomarkers to assist in the early detection of cancer. By acquiring MEDITE the company changed from solely research operations to an operating company with a well-developed infrastructure, 71 employees in four countries, a distribution network to about 70 countries worldwide, a well-known and established brand name and a wide range of products for anatomic pathology, histology and cytology laboratories.
Forward Looking Statement:
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding future operating performance, events, trends and plans. All statements other than statements of historical fact contained herein, including, without limitation, statements regarding our future financial position, business strategy, budgets, projected revenues and costs, and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expects," "intends," "plans," "projects," "estimates," "anticipates," or "believes" or the negative thereof or any variation thereon or similar terminology or expressions. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause our actual results to differ from our expectations, include but are not limited to, MEDITE's ability to maintain and grow its revenues, as well as those risk factors that apply to our operations as disclosed in Item 1A of our Report on Form 10-K for the year ended December 31, 2014 and other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on our forward-looking statements, as they speak only as of the date made. Such statements are not guarantees of future performance or events and we undertake no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances occurring after the date hereof.
For more information please visit: http://www.medite-group.com/.
Investor Contact:
Robert McCullough, Jr. CFO
407-996-9630
*LOGO for media: send2press.com/mediaboom/16-0107-medite-diag-300dpi.jpg
REF: OTCMKTS:MDIT
To view the original version on Send2Press Newswire, visit: https://www.send2press.com/newswire/medite-cancer-diagnostics-inc-will-present-at-the-seethruequity-healthcare-investor-conference-on-january-11-2016-0107-04.shtml.
NEWS SOURCE MEDITE Cancer Diagnostics, Inc. :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by and Copr. © 2016 Send2Press® Newswire, a service of Neotrope®.